Rachael Louise Brake - 13 Feb 2023 Form 4 Insider Report for Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Reporting relationship: Chief Scientific Officer
Issuer ticker: CRBP
Reported as of: 13 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Feb 2023, 11:56:03 UTC
Prior SEC filing: 02 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/Rachael Brake

Key filing fact

Rachael Louise Brake filed Form 4 for Corbus Pharmaceuticals Holdings, Inc. (CRBP) on 15 Feb 2023.

Key facts

This page summarizes Rachael Louise Brake's Form 4 filing for Corbus Pharmaceuticals Holdings, Inc. (CRBP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Feb 2023, 11:56.

Change

Previous filing in this sequence was filed on 02 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRBP transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +1,400,000
Change %
Price: $0.000000
Shares after: 1,400,000
Date: 13 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,400,000
Exercise price: $0.1420
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 13 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.